Patient information, communication and competence empowerment in oncology

Conditions

C00-C97 D45 D46 D47 D48

Schneider N, Altmann U, Brandt F, Hübner J, Strauss B, Keinki C.

2024-07-17

10.1007/s00520-024-08725-7

The impact of the COVID-19 pandemic restrictions on the health care utilization of cancer patients

Nico Schneider, Bernhard Strauß, Jutta Hübner, Christian Keinki, Florian Brandt et al. (7 authors)

BMC Cancer2023-05-1510 citations

10.1186/s12885-023-10945-9

Patient information, communication and competence empowerment in oncology: Results and learnings from the PIKKO study

Nico Schneider, Anna Bäcker, Bernhard Strauß, Jutta Hübner, Sabine Rubai et al. (12 authors)

Supportive Care in Cancer2023-05-083 citations

10.1007/s00520-023-07781-9

Patient information, communication and competence empowerment in oncology (PIKKO) - evaluation of a supportive care intervention for overall oncological patients. Study protocol of a non-randomized controlled trial.

Schneider N, Bäcker A, Brenk-Franz K, Keinki C, Hübner J, Brandt F, von der Winkel G, Hager L, Strauss B, Altmann U.

2020-05-159 citations

10.1186/s12874-020-01002-1

Interventions

Group 1: Treatment as usual additional advice and information path with patient navigators, oncological knowledge database, specialized oncological counseling Group 2: Treatment as usual, opportunity

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Diagnosis of diagnosis groups C00-C97 or D45-D48; initial diagnosis, relapse and transition to palliative care; treatment by doctors from the Saarland; insured with one of the health insurances participating in this study

Exclusion criteria

Exclusion criteria: statutory guardianship; insufficient knowledge of the German language; very strong visual and hearing impairment; dementia; mental limitations

Design outcomes

Primary

Measure	Time frame
Health-related quality of life (SF-12), measured by pre-intervention questionnaires plus 3 and 6 months after baseline	—

Secondary

Measure	Time frame
Self-efficacy (SWE), depression (PHQ9), anxiety (GAD7), health literacy (HLS-EU-47), treatment satisfaction (Qualiskope-A): measured with pre-intervention questionnaires plus 3 and 6 months after baseline. Furthermore, direct medical costs (days of inability to work, sick-pay, ambulant and hospital treatment, medication costs, use of psychotherapeutic treatments) are identified from secondary data analysis from health insurances.	—

Measure

Time frame

Self-efficacy (SWE), depression (PHQ9), anxiety (GAD7), health literacy (HLS-EU-47), treatment satisfaction (Qualiskope-A): measured with pre-intervention questionnaires plus 3 and 6 months after baseline. Furthermore, direct medical costs (days of inability to work, sick-pay, ambulant and hospital treatment, medication costs, use of psychotherapeutic treatments) are identified from secondary data analysis from health insurances.

—

Countries

Germany

Contacts

Public ContactChristian Keinki

Deutsche Krebsgesellschaft e.V.

keinki@krebsgesellschaft.de0157-86 85 92 44

Outcome results

None listed